Therapeutic treatment of abnormal cell growth with follicle regulatory protein

Abstract

A method of treating patients exhibiting neoplasms of gonadal origin is provided comprising administering a therapeutically effective dose of Follicle Regulatory Protein (FRP). The method may be used both pre- and post-operatively.

What is claimed is: 
     
       1. A method of therapeutically treating a patient exhibiting a neoplasm of gonadal origin, comprising: administering a therapeutically effective dose of Follicle Regulatory Protein (FRP) to said patient.   
     
     
       2. The method of claim 1 wherein said therapeutically effective dose is about 50 to 500 mg/M 2  of patient body surface/day of pure FRP. 
     
     
       3. The method of claim 1 wherein said therapeutically effective dose of FRP is determined through a chemosensitivity assay utilizing cells derived from the patient's neoplasm of gonadal origin. 
     
     
       4. The method of claim 1 wherein said neoplasm of gonodal origin is an adenocarcinoma of the ovary. 
     
     
       5. The method of claim 1 wherein said neoplasm of gonadal origin is a seminoma of the testes. 
     
     
       6. The method of claim 1 wherein said therapeutic treatment further comprises intramuscular injection of FRP. 
     
     
       7. The method of claim 1 wherein said therapeutic treatment further comprises continuous intravenous infusion of FRP. 
     
     
       8. The method of claim 1 wherein said therapeutic treatment is repeated as necessary to effect treatment. 
     
     
       9. A method of post-operatively treating a patient having previously had a neoplasm of gonadal origin surgically removed, comprising: administering a therapeutically effective dose of Follicle Regulatory Protein to said patient.   
     
     
       10. The method of claim 9 wherein said therapeutically effective dose is about 50 to 500 mg/M 2  of patient body surface/day of pure FRP. 
     
     
       11. The method of claim 9 wherein said therapeutically effective dose of FRP is determined through a chemosensitivity assay utilizing cells derived from the patient's neoplasm of gonadal origin. 
     
     
       12. The method of claim 9 wherein said neoplasm of gonadal origin is an adenocarcinoma of the ovary. 
     
     
       13. The method of claim 9 wherein said neoplasm of gonadal origin is a seminoma of the testes. 
     
     
       14. The method of claim 9 wherein said therapeutic treatment further comprises intramuscular injection of FRP. 
     
     
       15. The method of claim 9 wherein said therapeutic treatment further comprises continuous intravenous infusion of FRP. 
     
     
       16. The method of claim 9 wherein said therapeutic treatment is repeated as necessary to effect treatment.